National Institute Of Allergy And Infectious Diseases (niaid)
Clinical trials sponsored by National Institute Of Allergy And Infectious Diseases (niaid), explained in plain language.
-
Experimental HIV vaccine trial halted early – what we know
⭐️ VACCINE ⭐️ TerminatedThis early-stage study tested whether a new HIV vaccine was safe and could trigger an immune response in healthy adults aged 18 to 50. The vaccine was given alone or with other HIV vaccines in different schedules. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated May 15, 2026 11:54 UTC
-
Ebola vaccine spray trial halted early – what we learned
⭐️ VACCINE ⭐️ TerminatedThis early-stage study tested a nasal spray vaccine against Ebola in 15 healthy adults. The vaccine uses a weakened common cold virus to deliver a piece of the Ebola virus, aiming to teach the body to fight off infection. The trial was stopped early, but researchers were checking…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated May 08, 2026 12:01 UTC
-
New drug dosing study aims to preserve insulin in type 1 diabetes
Disease control TerminatedThis study tested four different doses of a drug called siplizumab in people aged 8 to 45 who were diagnosed with type 1 diabetes within the last 18 months. The goal was to find a safe dose that could help preserve the body's ability to produce insulin by changing certain immune …
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 16, 2026 23:55 UTC
-
New drug hope for rare autoimmune disease fizzles in early trial
Disease control TerminatedThis study tested the drug elotuzumab for people with active IgG4-related disease (IgG4-RD), a rare condition where the body attacks its own tissues. The trial aimed to see if adding elotuzumab to standard steroid treatment was safe and effective. Only 8 people enrolled before th…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
Lupus study aims to match drugs to immune profiles
Disease control TerminatedThis study tested two lupus medications—mycophenolate mofetil alone or with voclosporin—in 12 adults with moderate-to-severe lupus. Researchers wanted to see if treatment response differs based on a person's immune system type. The goal was to find better ways to tailor therapy, …
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo aims to tame tough rheumatoid arthritis
Disease control TerminatedThis study tested whether adding a 12-week course of VIB4920 to standard TNF-inhibitor therapy could improve disease control in people with rheumatoid arthritis who did not respond well to TNF-inhibitors alone. Only 2 participants were enrolled before the study was stopped. The g…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
Mpox drug trial ends early: did tecovirimat help?
Disease control TerminatedThis study tested whether the drug tecovirimat can safely treat mpox and speed up recovery. About 719 people with mpox took either tecovirimat or a placebo. The main goal was to see if the drug helped skin lesions heal faster and reduced pain. The trial was stopped early, and res…
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Shock therapy for Kids' arthritis? device trial halted early
Symptom relief TerminatedThis study tested a small device that sends mild electrical pulses through the skin to stimulate the vagus nerve, aiming to reduce pain and inflammation in children with juvenile idiopathic arthritis (JIA). The trial planned to enroll 18 participants aged 5-18, comparing the acti…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Symptom relief
Last updated May 16, 2026 23:49 UTC
-
HIV Drug-Hormone interaction study in transgender women halted early
Knowledge-focused TerminatedThis study looked at whether taking estrogen therapy changes the levels of HIV drugs in the blood of transgender women. About 93 adult transgender women living with HIV who were already on stable HIV treatment took part. The goal was to see if the HIV drugs still work well and if…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC